FindTrial
Sign In

A clinical trial of Trans-cranial Direct current stimulation in Depressive disorder.

Effect of adjuvant Trans-cranial Direct Current Stimulation on Cytokines, HPA axis & symptoms in Depressive disorder : A pilot RCT

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/05/052214
Enrollment
60
Registered
2023-05-02
Start date
Unknown
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F320- Major depressive disorder, singleepisode, mild Health Condition 2: F321- Major depressive disorder, singleepisode, moderate Health Condition 3: F322- Major depressive disorder, singleepisode, severe without psychotic features

Interventions

Intervention1: Transcranial direct current stimulation (tDCS): tDCS uses weak polarizing currents delivered through scalp electrodes to alter cortical neuron excitability. This paradigm of tDCS treatm

Sponsors

Armed Forces Medical Research Council
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with Depressive disorder without psychotic features currently experiencing an acute depressive episode aged between 18-60 years and consenting for the study will be enrolled. Comorbid anxiety symptoms will be permitted.

Exclusion criteria

Exclusion criteria: 1. Those diagnosed with Neurodevelopmental disorders, Schizophrenia/ psychotic disorders, BPAD, OCD, Dissociative disorders, Eating disorders, Alcohol and Substance use disorders. 2. Neurological conditions like Movement disorders, Multiple sclerosis, Epilepsy, Cerebrovascular diseases and CNS infections. 3. Those having uncontrolled Diabetes, Hypertension or acute or chronic inflammatory conditions. 4. Those with history of endocrine diseases involving disorders of thyroid gland, parathyroid gland and adrenal gland. 5. Pregnant or lactating patients. 6. Those on anti-inflammatory drugs like NSAIDs and corticosteroids. 7. Those who have received any other form of neurostimulation in last 06 months.

Design outcomes

Primary

MeasureTime frame
To study the impact of tDCS on levels of Cytokines, Cortisol and serum ACTH in patients of Depressive disorder. Plasma IL-2, IL-4, IL-6, IL-10, IL-17a, Interferon (IFN)-?, TNF-a, basal cortisol and ACTH will be measured.Timepoint: At baseline and after 6 weeks—

Secondary

MeasureTime frame
To determine the impact of tDCS on symptoms of depression measured by Hamilton Depression Rating Scale (HDRS)Timepoint: At baseline and after 6 weeks—

Countries

India

Contacts

Public ContactSrikrishna Prasad Panda

Armed Forces Medical College

drsppanda@gmail.com7972280934

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026